MyChesCo on MSN2h
AstraZeneca’s AZD0780 Shows Promising Results in Cholesterol-Lowering Clinical TrialNew data from the PURSUIT Phase IIb trial reveal AstraZeneca‘s investigational oral PCSK9 inhibitor, AZD0780, delivers ...
AstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 ...
AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...
AstraZeneca’s AZD0780 is an investigational oral medication that was developed to lower low-density lipoprotein cholesterol ...
Positive results from the PURSUIT Phase IIb trial of AstraZeneca’s AZD0780 have shown a statistically significant low-density ...
AstraZeneca’s AZD0780, a novel oral PCSK9 inhibitor, demonstrates significant LDL cholesterol reduction in PURSUIT phase IIb trial: Cambridge, UK Wednesday, April 2, 2025, 11:00 ...
New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of ...
New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of standard of care WILMINGTON, Del.--( ...
Oral PCSK9 inhibitor, AZD0780, demonstrated a significant 50.7% reduction in LDL cholesterol levels in the Phase IIb PURSUIT ...
The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback